Shionogi’s COVID-19 treatment Xocova was found to reduce the risk of developing at least one of the symptoms of long COVID-19, the Osaka-based pharmaceutical company said Wednesday.

Shionogi, which has yet to publish its results in a journal, presented the data at an academic conference held in the U.S. this week.

The data was obtained through a follow-up study of patients with mild or moderate COVID-19 registered in a clinical trial for the approval of Xocova as a treatment for the virus. The drug received emergency approval in Japan in November as the third oral treatment available in the country and the first to be developed domestically.